34 results on '"Sullman, Mark"'
Search Results
2. Burden of diseases due to high systolic blood pressure in the Middle East and North Africa region from 1990 to 2019
- Author
-
Safiri, Saeid, Mousavi, Seyed Ehsan, Motlagh Asghari, Kimia, Nejadghaderi, Seyed Aria, Aletaha, Reza, Sullman, Mark J. M., Singh, Kuljit, Kolahi, Ali-Asghar, and Beyranvand, Mohammad Reza
- Published
- 2024
- Full Text
- View/download PDF
3. The burden of schizophrenia in the Middle East and North Africa region, 1990–2019
- Author
-
Safiri, Saeid, Noori, Maryam, Nejadghaderi, Seyed Aria, Shamekh, Ali, Sullman, Mark J. M., Collins, Gary S., and Kolahi, Ali-Asghar
- Published
- 2024
- Full Text
- View/download PDF
4. The burden of dermatitis from 1990–2019 in the Middle East and North Africa region
- Author
-
Safiri, Saeid, Jaberinezhad, Mehran, Mousavi, Seyed Ehsan, Motlagh Asghari, Kimia, Shamekh, Ali, Nejadghaderi, Seyed Aria, Sullman, Mark J. M., Houshyar, Yousef, Behrangi, Elham, and Kolahi, Ali-Asghar
- Published
- 2024
- Full Text
- View/download PDF
5. The burden of Parkinson’s disease in the Middle East and North Africa region, 1990–2019: results from the global burden of disease study 2019
- Author
-
Safiri, Saeid, Noori, Maryam, Nejadghaderi, Seyed Aria, Mousavi, Seyed Ehsan, Sullman, Mark J. M., Araj-Khodaei, Mostafa, Singh, Kuljit, Kolahi, Ali-Asghar, and Gharagozli, Kurosh
- Published
- 2023
- Full Text
- View/download PDF
6. The burden of low back pain and its association with socio-demographic variables in the Middle East and North Africa region, 1990–2019
- Author
-
Safiri, Saeid, Nejadghaderi, Seyed Aria, Noori, Maryam, Sullman, Mark J. M., Collins, Gary S., Kaufman, Jay S., Hill, Catherine L., and Kolahi, Ali-Asghar
- Published
- 2023
- Full Text
- View/download PDF
7. Burden of female breast cancer in the Middle East and North Africa region, 1990–2019
- Author
-
Safiri, Saeid, Noori, Maryam, Nejadghaderi, Seyed Aria, Sullman, Mark J. M., Bragazzi, Nicola Luigi, Almasi-Hashiani, Amir, Mansournia, Mohammad Ali, and Kolahi, Ali-Asghar
- Published
- 2022
- Full Text
- View/download PDF
8. The burden of chronic obstructive pulmonary disease and its attributable risk factors in the Middle East and North Africa region, 1990–2019
- Author
-
Feizi, Hamidreza, Alizadeh, Mahasti, Nejadghaderi, Seyed Aria, Noori, Maryam, Sullman, Mark J. M., Ahmadian Heris, Javad, Kolahi, Ali-Asghar, Collins, Gary S., and Safiri, Saeid
- Published
- 2022
- Full Text
- View/download PDF
9. Burden of tension-type headache in the Middle East and North Africa region, 1990-2019
- Author
-
Safiri, Saeid, Kolahi, Ali-Asghar, Noori, Maryam, Nejadghaderi, Seyed Aria, Aslani, Armin, Sullman, Mark J. M., Farhoudi, Mehdi, Araj-Khodaei, Mostafa, Collins, Gary S., Kaufman, Jay S., and Gharagozli, Kurosh
- Published
- 2022
- Full Text
- View/download PDF
10. Comparison of the burden of anorexia nervosa in the Middle East and North Africa region between 1990 and 2019
- Author
-
Safiri, Saeid, Noori, Maryam, Nejadghaderi, Seyed Aria, Mousavi, Seyed Ehsan, Karamzad, Nahid, Sullman, Mark J. M., Pirotta, Stephanie, Collins, Gary S., Abdollahi, Morteza, and Kolahi, Ali-Asghar
- Published
- 2022
- Full Text
- View/download PDF
11. Neck pain: global epidemiology, trends and risk factors
- Author
-
Kazeminasab, Somaye, Nejadghaderi, Seyed Aria, Amiri, Parastoo, Pourfathi, Hojjat, Araj-Khodaei, Mostafa, Sullman, Mark J. M., Kolahi, Ali-Asghar, and Safiri, Saeid
- Published
- 2022
- Full Text
- View/download PDF
12. The burden of major depressive disorder in the Middle East and North Africa region, 1990–2019.
- Author
-
Safiri, Saeid, Mousavi, Seyed Ehsan, Nejadghaderi, Seyed Aria, Noori, Maryam, Sullman, Mark J. M., Kolahi, Ali-Asghar, and Shekarriz-Foumani, Reza
- Subjects
MENTAL depression ,GLOBAL burden of disease ,AGE groups - Abstract
Background: Major depressive disorder (MDD) is one of the leading causes of disability. We aimed to report the MDD-attributable prevalence, incidence and years lived with disability (YLDs) in the Middle East and North Africa (MENA) region from 1990 to 2019 by age, sex and socio-demographic index (SDI). Methods: Publicly available data on the burden of MDD were retrieved from the Global Burden of Disease (GBD) study 2019 for the 21 countries in MENA. The counts and age-standardised rates (per 100,000) were presented, along with their corresponding 95% uncertainty intervals. Results: In 2019, MDD had an age-standardised point prevalence of 3322.1 and an incidence rate of 4921.7 per 100,000 population in MENA. Furthermore, there were 4.1 million YLDs in 2019. However, there were no substantial changes in the MDD burden over the period 1990–2019. In 2019, Palestine had the highest burden of MDD. The highest prevalence, incidence and YLDs attributable to MDD were found in the 35–39 age group. In 2019, the YLD rate in MENA was higher than the global rate for almost all age groups. Furthermore, there was a broadly negative association between the YLD rate and SDI. Conclusion: The study highlights the need to prevent the disorder using a multidisciplinary approach and for the provision of cost-effective treatments for those affected, in order to increase their quality of life. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
13. Burden of anemia and its underlying causes in 204 countries and territories, 1990–2019: results from the Global Burden of Disease Study 2019
- Author
-
Safiri, Saeid, Kolahi, Ali-Asghar, Noori, Maryam, Nejadghaderi, Seyed Aria, Karamzad, Nahid, Bragazzi, Nicola Luigi, Sullman, Mark J. M., Abdollahi, Morteza, Collins, Gary S., Kaufman, Jay S., and Grieger, Jessica A.
- Published
- 2021
- Full Text
- View/download PDF
14. The burden of rheumatic heart disease in the Middle East and North Africa region, 1990−2019.
- Author
-
Safiri, Saeid, Mousavi, Seyed Ehsan, Noori, Maryam, Nejadghaderi, Seyed Aria, Sullman, Mark J.M., Singh, Kuljit, and Kolahi, Ali-Asghar
- Abstract
• Age-standardized point prevalence of RHD was 388.9/100,000 in MENA in 2019. • Highest age-standardized DALY rate of RHD in 2019 was in Afghanistan. • Age-standardized point prevalence of RHD was highest in middle-age group. • Burden of RHD was negatively associated with the SDI over 1990–2019. Rheumatic heart disease (RHD) is a treatable and preventable condition resulting from acute rheumatic fever. To report the prevalence, mortality and disability-adjusted life-years (DALY) due to RHD in the Middle East and North Africa (MENA) region from 1990 to 2019, by sex, age group, country and sociodemographic index (SDI). Information on the prevalence, mortality and DALY associated with RHD were obtained from the Global Burden of Disease Study 2019. Data were gathered for all countries in the MENA region over the period 1990–2019. These data included counts and age-standardized rates per 100,000, accompanied by 95% uncertainty intervals (UIs). The MENA region had an age-standardized point prevalence of 388.9 per 100,000 in 2019, which was 5.4% higher than in 1990. The annual incidence rate was 1.6, which was 63.4% lower than in 1990. There were 379.4 thousand DALY attributable to RHD in 2019, with an age-standardized rate of 67.1, which was 61.3% lower than in 1990. In 2019, an estimated 7.4 thousand deaths were due to RHD, and the age-standardized death rate was 63.4% lower in 2019 than in 1990. DALY rates rose steadily with increasing age in both males and females. The SDI correlated negatively with the rate of DALY for RHD throughout the study period. The burden of RHD in MENA declined from 1990 to 2019, demonstrating the importance of regularly updating health data and identifying risk factors, and developing effective guidelines on prevention. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
15. The burden of neck pain among adults aged 70 years and older in Iran, 1990–2019.
- Author
-
Nejadghaderi, Seyed Aria, Mousavi, Seyed Ehsan, Sullman, Mark J. M., Kolahi, Ali‐Asghar, Namazi Shabestari, Alireza, and Safiri, Saeid
- Subjects
NECK pain ,OLDER people ,GLOBAL burden of disease - Abstract
Background: Neck pain is a complex musculoskeletal disorder that can result in substantial morbidity. The present article presents the neck pain burden in Iranians who were at least 70 years old, from 1990 to 2019, by sex, age group, and province. Methods: Publicly available information on the prevalence, incidence, and years lived with disability (YLD) caused by neck pain was extracted from the Global Burden of Disease study 2019. The estimates were all provided as counts and age‐standardized rates (per 100,000), and included 95% uncertainty intervals. Results: The point prevalence of neck pain in 2019 was 8710.6, while the incidence rate was 1334.7 per 100,000 population. That same year, there were number of 27.8 thousand YLDs and an YLD rate of 801.7 per 100,000. The prevalence, incidence, and YLD rates did not change substantially over the measurement period (1990–2019). The highest YLD rate was found in Tehran (960.9 per 100,000), while Kohgiluyeh and Boyer‐Ahmad had the lowest (730.5 per 100,000). Females had slightly higher prevalent cases, incident cases, and YLDs, as well as their corresponding rates in 2019. In 2019, the number of prevalent cases, incident cases, and YLDs peaked in the 70–74 age group, for both sexes, and in all cases they reduced with age. In both 1990 and 2019, Iran had a higher YLD rate than that found among elderly adults in the Middle East and North Africa region. Conclusions: The burden of neck pain in Iran has decreased slightly over the last three decades, but it still imposes a substantial burden and is higher than that found in the rest of the region. Therefore, preventive programs should be initiated at a young age to reduce the attributable burden later in life. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
16. The Burden of Attention-Deficit Hyperactivity Disorder (ADHD) in the Middle East and North Africa Region, 1990 to 2019.
- Author
-
Safiri, Saeid, Mousavi, Seyed Ehsan, Nejadghaderi, Seyed Aria, Noori, Maryam, Sullman, Mark J. M., Amiri, Shahrokh, and Kolahi, Ali-Asghar
- Subjects
ATTENTION-deficit hyperactivity disorder ,GENDER differences (Sociology) ,GLOBAL burden of disease - Abstract
Objective: To report the burden of ADHD in the Middle East and North Africa (MENA) region from 1990 to 2019. Methods: Publicly available data on the burden of ADHD were retrieved from the Global Burden of Disease study 2019. The counts and age-standardized rates (per 100,000) were presented. Results: In 2019, ADHD had an age-standardized point prevalence of 1245.1 and a years lived with disability (YLD) rate of 15.1 per 100,000 in MENA, which were 7.2% (−11 to −3.3) and 7.2% (−11.2 to −2.7) lower, respectively, than in 1990. The highest YLD rate of ADHD was found in the 10 to 14 age group and there were no remarkable differences between males and females. No clear association was found between the YLD rate and the socio-demographic index. Conclusion: The burden of ADHD in the MENA region decreased over the period 1990 to 2019, and regularly updating the epidemiological information is suggested. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
17. Non‐spinal low back pain: Global epidemiology, trends, and risk factors.
- Author
-
Shokri, Pourya, Zahmatyar, Mahdi, Falah Tafti, Mahdi, Fathy, Mobin, Rezaei Tolzali, Mohammadmahdi, Ghaffari Jolfayi, Amir, Nejadghaderi, Seyed Aria, Sullman, Mark J. M., Kolahi, Ali‐Asghar, and Safiri, Saeid
- Abstract
Background and Aims: Low back pain (LBP) is one of the most debilitating and prevalent disorders. The prevalence of LBP ranges from 30% to 80%, depending on the population, and increases with age. Causes of LBP are typically classified as spinal and non‐spinal. The main goal of this study was to investigate the non‐spinal causes of LBP, since neglecting these factors leads to increases in the financial, psychological, and physical burden of LBP on individuals as well as on society. Methods: The data were extracted after searching the PubMed database and Google Scholar search engine up to October 27, 2021. We included all studies that were conducted on a human population and assessed the effects of epidemiological, biological, psychological, and sociodemographic factors on the incidence or progression of LBP. Results: The most common causes of non‐spinal LBP were diseases such as nephrolithiasis, endometriosis, tumors, fibromyalgia, and conditions like psychological disorders and pregnancy. Nevertheless, the perceived intensity of the pain can be affected by factors such as socioeconomic level, genetics, age, habits, diet, and psychological status. Conclusion: The epidemiology, etiologies, and risk factors associated with LBP should be more clearly recognized to better prevent, diagnose, and treat the underlying disease and to reduce the burden of LBP. Key points: Low back pain (LBP) is a highly prevalent and incapacitating condition, affecting a significant portion of the population.LBP can arise from various sources, categorized as spinal and non‐spinal causes.There are several non‐spinal causes of back pain, including conditions like nephrolithiasis, endometriosis, tumors, fibromyalgia, psychological disorders, and pregnancy. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
18. The burden of pancreatic cancer and its attributable risk factors in the Middle East and North Africa region, 1990–2019.
- Author
-
Nejadghaderi, Seyed Aria, Kolahi, Ali‐Asghar, Noori, Maryam, Sullman, Mark J M, and Safiri, Saeid
- Subjects
PANCREATIC cancer ,GLOBAL burden of disease ,BODY mass index ,BLOOD sugar - Abstract
Background and Aim: Globally, pancreatic cancer is recognized as one of the most lethal types of cancers. We report the burden of pancreatic cancer and its attributable risk factors in the Middle East and North Africa (MENA) region, from 1990 to 2019, by age, sex, and socio‐demographic index. Methods: Publicly available data from the Global Burden of Disease 2019 study were used to report the incidence, deaths, and disability‐adjusted life years (DALYs) attributable to pancreatic cancer, as counts and age‐standardized rates with 95% uncertainty intervals. Results: In 2019, pancreatic cancer had an age‐standardized incidence rate of 5.3 and a death rate of 5.5 (per 100 000) in MENA, which have increased by 97.5% and 93.4%, respectively, since 1990. There were 563.6 thousand DALYs attributable to pancreatic cancer in 2019, with an age‐standardized DALY rate of 123.0, which has increased by 84.9% since 1990. The highest number of incident cases was found in the 60–64 and 65–69 age groups, among male and female, respectively. In addition, the MENA/global DALY ratios were higher in all age groups for both sexes in 2019, than they were in 1990. There was a positive association between socio‐demographic index and the burden of pancreatic cancer. Smoking, high fasting plasma glucose, and high body mass index were responsible for 19.2%, 9.3%, and 9.3% of the attributable DALYs in 2019, respectively. Conclusions: There was a clear and substantial increase in the burden of pancreatic cancer in the MENA region. Prevention programs should be implemented in the region that target these three risk factors. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
19. burden of Alzheimer's disease and other types of dementia in the Middle East and North Africa region, 1990–2019.
- Author
-
Safiri, Saeid, Noori, Maryam, Nejadghaderi, Seyed Aria, Mousavi, Seyed Ehsan, Sullman, Mark J M, Araj-Khodaei, Mostafa, Collins, Gary S, Kolahi, Ali-Asghar, and Gharagozli, Kurosh
- Subjects
ALZHEIMER'S disease ,GLOBAL burden of disease ,AGE distribution ,LIFE expectancy ,SEX distribution ,DEMENTIA ,DESCRIPTIVE statistics ,SOCIODEMOGRAPHIC factors ,PEOPLE with disabilities ,DISEASE complications - Abstract
Background Alzheimer's disease (AD) is the most common cause of dementia and this progressive neurological disorder is associated with substantial mortality and morbidity. We aimed to report the burden of AD and other types of dementia in the Middle East and North Africa (MENA) region, by age, sex and sociodemographic index (SDI), for the period 1990–2019. Methods publicly accessible data on the prevalence, death and disability-adjusted life years (DALYs) because of AD, and other types of dementia, were retrieved from the global burden of disease 2019 project for all MENA countries from 1990 to 2019. Results in 2019, the age-standardised point prevalence of dementia was 777.6 per 100,000 populations in MENA, which was 3.0% higher than in 1990. The age-standardised death and DALY rates of dementia were 25.5 and 387.0 per 100,000, respectively. In 2019, the highest DALY rate was observed in Afghanistan and the lowest rate was in Egypt. That same year, the age-standardised point prevalence, death and DALY rates increased with advancing age and were higher for females of all age groups. From 1990 to 2019, the DALY rate of dementia decreased with increasing SDI up to 0.4, then slightly increased up to an SDI of 0.75, followed by a decrease for the remaining SDI levels. Conclusions the point prevalence of AD and other types of dementia has increased over the past three decades, and in 2019, the corresponding regional burden was higher than the global average. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
20. The estimated burden of bulimia nervosa in the Middle East and North Africa region, 1990–2019.
- Author
-
Safiri, Saeid, Noori, Maryam, Nejadghaderi, Seyed Aria, Shamekh, Ali, Karamzad, Nahid, Sullman, Mark J. M., Grieger, Jessica A., Collins, Gary S., Abdollahi, Morteza, and Kolahi, Ali‐Asghar
- Subjects
STATISTICS ,TIME ,LIFE expectancy ,AGE distribution ,GLOBAL burden of disease ,MEDICAL care costs ,SEX distribution ,BULIMIA ,RESEARCH funding ,DESCRIPTIVE statistics ,PEOPLE with disabilities ,SOCIODEMOGRAPHIC factors ,DATA analysis - Abstract
Objective: We aimed to report the burden of bulimia nervosa (BN) in the Middle East and North Africa (MENA) region by age, sex, and sociodemographic index (SDI), for the period 1990–2019. Methods: Estimates of the prevalence, incidence, and disability‐adjusted life‐years (DALYs) attributable to BN were retrieved from the Global Burden of Disease study 2019, between 1990 and 2019, for the 21 countries in the MENA region. The counts and age‐standardized rates (per 100,000) were presented, along with their corresponding 95% uncertainty intervals. Results: In 2019, the estimated regional age‐standardized point prevalence and incidence rates of BN were 168.3 (115.0–229.6) and 178.6 (117.0–255.6) per 100,000, which represented 22.0% (17.5–27.2) and 10.4% (7.1–14.7) increases, respectively, since 1990. Moreover, in 2019 the regional age‐standardized DALY rate was 35.5 (20.6–55.5) per 100,000, which was 22.2% (16.7–28.2) higher than in 1990. In 2019, Qatar (58.6 [34.3–92.5]) and Afghanistan (18.4 [10.6–29.2]) had the highest and lowest age‐standardized DALY rates, respectively. Regionally, the age‐standardized point prevalence of BN peaked in the 30–34 age group and was more prevalent among women. In addition, there was a generally positive association between SDI and the burden of BN across the measurement period. Discussion: In the MENA region, the burden of BN has increased over the last three decades. Cost‐effective preventive measures are needed in the region, especially in the high SDI countries. Public Significance: This study reports the estimated burden of BN in the MENA region and shows that its burden has increased over the last three decades. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
21. Global, regional and national burden of bladder cancer and its attributable risk factors in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease study 2019
- Author
-
Safiri, Saeid, Kolahi, Ali-Asghar, Naghavi, Mohsen, Nejadghaderi, Seyed Aria, Mansournia, Mohammad Ali, Sullman, Mark, Almasi-Hashiani, Amir, Sepidarkish, Mahdi, Ashrafi-Asgarabad, Ahad, Abdoli, Amir, Abu-Gharbieh, Eman, Advani, Shailesh M., Alahdab, Fares, Alipour, Vahid, Amini, Erfan, Anbesu, Etsay Woldu, Anderson, Jason A., Arabloo, Jalal, Awedew, Atalel Fentahun, Baig, Atif Amin, Bhagavathula, Akshaya Srikanth, Bijani, Ali, Biondi, Antonio, Bjørge, Tone, Braithwaite, Dejana, Caetano dos Santos, Florentino Luciano, Carreras, Giulia, Carvalho, Felix, Chu, Dinh-Toi, Compton, Kelly, Costa, Vera Marisa, Dai, Xiaochen, Dandona, Lalit, Dandona, Rakhi, Molla, Meseret Derbew, Desta, Abebaw Alemayehu, Dianatinasab, Mostafa, Ebrahimi, Hedyeh, Eftekharzadeh, Sahar, El Sayed, Iman, Eshrati, Babak, Farzadfar, Farshad, Feleke, Berhanu Elfu, Fernandes, Eduarda, Filip, Irina, Fomenkov, Artem Alekseevich, Gallus, Silvano, Ghafourifard, Mansour, Ghashghaee, Ahmad, Golechha, Mahaveer, Gonfa, Kebebe Bekele, Gorini, Giuseppe, Hafezi-Nejad, Nima, Hamidi, Samer, Harvey, James D., Hassanipour, Soheil, Hay, Simon I., Henrikson, Hannah Jacqueline, Househ, Mowafa, Ibitoye, Segun Emmanuel, Ilesanmi, Olayinka Stephen, Ilic, Irena M., Ilic, Milena D., Joukar, Farahnaz, Kumar, G. Anil, La Vecchia, Carlo, Ladi-Seyedian, Seyedeh-Sanam, Lami, Faris Hasan, Landires, Iván, Li, Bingyu, Lugo, Alessandra, Majeed, Azeem, Malekzadeh, Reza, Mestrovic, Tomislav, Miazgowski, Bartosz, Michalek, Irmina Maria, Moghadaszadeh, Masoud, Mohamad, Osama, Mohammadian-Hafshejani, Abdollah, Reza, Mohammadpourhodki, Mohammed, Shafiu, Mokdad, Ali H., Molokhia, Mariam, Monasta, Lorenzo, Moradzadeh, Rahmatollah, Nabavizadeh, Behnam, Naimzada, Mukhammad David, Nguyen, Cuong Tat, Nguyen, Huong Lan Thi, Nikbakhsh, Rajan, Nowroozi, Mohammad Reza, Nuñez-Samudio, Virginia, Otstavnov, Stanislav S., Pham, Hai Quang, Pirestani, Majid, Pottoo, Faheem Hyder, Rabiee, Navid, Radfar, Amir, Rafiei, Alireza, Rathi, Priya, Rawaf, David Laith, Rawaf, Salman, Rezaei, Nima, Roberts, Nicholas L.S., Roshandel, Gholamreza, Samy, Abdallah M., Sepanlou, Sadaf G., Sha, Feng, Shaikh, Masood Ali, Sheikhbahaei, Sara, Malleshappa, Sudeep K. Siddappa, Singh, Jasvinder A., Spurlock, Emma Elizabeth, Tadesse, Eyayou Girma, Tefera, Yonas Getaye, Tekalegn, Yohannes, Titova, Mariya Vladimirovna, Topor-Madry, Roman, Traini, Eugenio, Tran, Bach Xuan, Tran, Khanh Bao, Travillian, Ravensara S., Vacante, Marco, Xu, Rixing, Yeshitila, Yordanos Gizachew, Zadnik, Vesna, Zamanian, Maryam, and Zhang, Zhi-Jiang
- Subjects
Male ,Medicine (General) ,Sociodemographic Factors ,ALCOHOL-CONSUMPTION ,Population ,Infectious and parasitic diseases ,RC109-216 ,Global Burden of Disease Bladder Cancer Collaborators ,Global Burden of Disease ,R5-920 ,Risk Factors ,Medicine ,cancer ,Humans ,education ,METAANALYSIS ,VEGETABLES ,Bladder cancer ,Epidemiology ,Global burden ,Public, Environmental & Occupational Health ,Cause of death ,Original Research ,education.field_of_study ,Science & Technology ,TEA ,FRUIT ,business.industry ,MORTALITY ,Health Policy ,Incidence (epidemiology) ,Mortality rate ,Public Health, Environmental and Occupational Health ,Disability-Adjusted Life Years ,ASSOCIATION ,medicine.disease ,Years of potential life lost ,Urinary Bladder Neoplasms ,Attributable risk ,Life expectancy ,epidemiology ,Female ,Quality-Adjusted Life Years ,business ,Life Sciences & Biomedicine ,Demography - Abstract
IntroductionThe current study determined the level and trends associated with the incidence, death and disability rates for bladder cancer and its attributable risk factors in 204 countries and territories, from 1990 to 2019, by age, sex and sociodemographic index (SDI; a composite measure of sociodemographic factors).MethodsVarious data sources from different countries, including vital registration and cancer registries were used to generate estimates. Mortality data and incidence data transformed to mortality estimates using the mortality to incidence ratio (MIR) were used in a cause of death ensemble model to estimate mortality. Mortality estimates were divided by the MIR to produce incidence estimates. Prevalence was calculated using incidence and MIR-based survival estimates. Age-specific mortality and standardised life expectancy were used to estimate years of life lost (YLLs). Prevalence was multiplied by disability weights to estimate years lived with disability (YLDs), while disability-adjusted life years (DALYs) are the sum of the YLLs and YLDs. All estimates were presented as counts and age-standardised rates per 100 000 population.ResultsGlobally, there were 524 000 bladder cancer incident cases (95% uncertainty interval 476 000 to 569 000) and 229 000 bladder cancer deaths (211 000 to 243 000) in 2019. Age-standardised death rate decreased by 15.7% (8.6 to 21.0), during the period 1990–2019. Bladder cancer accounted for 4.39 million (4.09 to 4.70) DALYs in 2019, and the age-standardised DALY rate decreased significantly by 18.6% (11.2 to 24.3) during the period 1990–2019. In 2019, Monaco had the highest age-standardised incidence rate (31.9 cases (23.3 to 56.9) per 100 000), while Lebanon had the highest age-standardised death rate (10.4 (8.1 to 13.7)). Cabo Verde had the highest increase in age-standardised incidence (284.2% (214.1 to 362.8)) and death rates (190.3% (139.3 to 251.1)) between 1990 and 2019. In 2019, the global age-standardised incidence and death rates were higher among males than females, across all age groups and peaked in the 95+ age group. Globally, 36.8% (28.5 to 44.0) of bladder cancer DALYs were attributable to smoking, more so in males than females (43.7% (34.0 to 51.8) vs 15.2% (10.9 to 19.4)). In addition, 9.1% (1.9 to 19.6) of the DALYs were attributable to elevated fasting plasma glucose (FPG) (males 9.3% (1.6 to 20.9); females 8.4% (1.6 to 19.1)).ConclusionsThere was considerable variation in the burden of bladder cancer between countries during the period 1990–2019. Although there was a clear global decrease in the age-standardised death, and DALY rates, some countries experienced an increase in these rates. National policy makers should learn from these differences, and allocate resources for preventative measures, based on their country-specific estimates. In addition, smoking and elevated FPG play an important role in the burden of bladder cancer and need to be addressed with prevention programmes.
- Published
- 2021
22. Prevalence, incidence and years lived with disability due to polycystic ovary syndrome in 204 countries and territories, 1990-2019.
- Author
-
Safiri, Saeid, Noori, Maryam, Nejadghaderi, Seyed Aria, Karamzad, Nahid, Carson-Chahhoud, Kristin, Sullman, Mark J M, Collins, Gary S, Kolahi, Ali-Asghar, and Avery, Jodie
- Abstract
Study Question: What is the global, regional and national burden of polycystic ovary syndrome (PCOS), by age and socio-demographic index (SDI), over the period 1990-2019?Summary Answer: In 2019, the global age-standardized point prevalence, incidence and years lived with disability (YLD) of PCOS were 30.4, 29.5 and 29.9 per 100 000 population, respectively.What Is Known Already: Data from the Global Burden of Disease (GBD) study 2017 showed that the global age-standardized PCOS incidence rate increased 1.45% over the period 1990-2017.Study Design, Size, Duration: A systematic analysis of the PCOS prevalence, incidence and YLDs across 204 countries and territories was performed.Participants/materials, Setting, Methods: Data on the point prevalence, annual incidence and YLDs due to PCOS were retrieved from the GBD study 2019 for 204 countries and territories from 1990 to 2019. The counts and age-standardized rates (per 100 000) are presented, along with their corresponding 95% uncertainty intervals (UIs).Main Results and the Role Of Chance: In 2019, the global age-standardized point prevalence and annual incidence rates for PCOS were 1677.8 (95% UI: 1166.0 to 2192.4) and 59.8 (95% UI: 41.7 to 78.9) per 100 000, which represents a 30.4% and 29.5% increase since 1990, respectively. Moreover, the global age-standardized YLD rate in 2019 was 14.7 (6.3-29.5), an increase of 29.9% since 1990. In 2019, Italy (7897.0), Japan (6298.7) and New Zealand (5419.1) had the highest estimated age-standardized point prevalences of PCOS. Globally, the number of prevalent cases and the point prevalence of PCOS peaked in the 25-29 years and 40-44 years age groups, respectively. Positive associations were found between the burden of PCOS and the SDI at the regional and national levels.Limitations, Reasons For Caution: Variations in how PCOS was defined is a major limitation that prevents valid comparisons between different regions.Wider Implications Of the Findings: Globally, the burden of PCOS has increased at an alarming rate, making it a major public health concern. Increasing public awareness about this common condition, improving management options and increasing support to reduce factors which lead to further complications, need to be public health priorities.Study Funding/competing Interest(s): The Bill and Melinda Gates Foundation, who were not involved in any way in the preparation of this manuscript, funded the GBD study. The Shahid Beheshti University of Medical Sciences, Tehran, Iran (Grant No. 28709) also supported the present report. The authors declare no competing interests.Trial Registration Number: N/A. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
23. Global, Regional and National Burden of Cancers Attributable to High Fasting Plasma Glucose in 204 Countries and Territories, 1990-2019.
- Author
-
Safiri, Saeid, Nejadghaderi, Seyed Aria, Karamzad, Nahid, Kaufman, Jay S., Carson-Chahhoud, Kristin, Bragazzi, Nicola Luigi, Sullman, Mark J. M., Beyranvand, Mohammad Reza, Mansournia, Mohammad Ali, Almasi-Hashiani, Amir, Collins, Gary S., and Kolahi, Ali-Asghar
- Subjects
BLOOD sugar ,GLOBAL burden of disease ,AGE groups ,DEATH rate ,DEVELOPED countries - Abstract
Background: To report the burden of cancers attributable to high fasting plasma glucose (HFPG) by sex, age, location, cancer type and Socio-demographic Index (SDI) over the period 1990 to 2019 for 204 countries and territories. Methods: Using the Comparative Risk Assessment approach of Global Burden of Disease (GBD) study 2019, the burden of cancers attributable to HFPG was reported in 1990 and 2019. Results: Globally, in 2019 there were an estimated 419.3 thousand cancer deaths (95% UI: 115.7 to 848.5) and 8.6 million cancer DALYs (2.4 to 17.6) attributable to HFPG. By sex, 4.6 (1.1 to 9.9) and 4.0 (1.1 to 8.4) million global cancer DALYs were attributable to HFPG in men and women, respectively. The global age-standardized death and DALY rates of cancers attributable to HFPG (per 100,000) have increased by 27.8% (20.5 to 38.7%) and 24.5% (16.4 to 35.6%), respectively, since 1990. High-income North America (9.5 [2.7 to 18.8]) and Eastern Sub-Saharan Africa (2.0 [0.5 to 4.2]) had the highest and lowest regional age-standardized death rates, respectively, for cancers attributable to HFPG. In 2019, the global number of attributable cancer DALYs were highest in 65-69 age group. Moreover, there was an overall positive association between SDI and the regional age-standardized DALY rate for HFPG-attributable cancers. Conclusions: HFPG was associated with more burden in 2019. Preventive programs for diabetes and screening of individuals with diabetes for cancers, especially in older males living in developed countries, are required to arrest the large increases in HFPGattributable cancers. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
24. Migraine: A Review on Its History, Global Epidemiology, Risk Factors, and Comorbidities.
- Author
-
Amiri, Parastoo, Kazeminasab, Somayeh, Nejadghaderi, Seyed Aria, Mohammadinasab, Reza, Pourfathi, Hojjat, Araj-Khodaei, Mostafa, Sullman, Mark J. M., Kolahi, Ali-Asghar, and Safiri, Saeid
- Subjects
MIGRAINE ,EPIDEMIOLOGY ,SLEEP interruptions ,YOUNG adults ,MIGRAINE aura ,AUTOIMMUNE diseases ,COMORBIDITY - Abstract
Migraine affects more than one billion individuals each year across the world, and is one of the most common neurologic disorders, with a high prevalence and morbidity, especially among young adults and females. Migraine is associated with a wide range of comorbidities, which range from stress and sleep disturbances to suicide. The complex and largely unclear mechanisms of migraine development have resulted in the proposal of various social and biological risk factors, such as hormonal imbalances, genetic and epigenetic influences, as well as cardiovascular, neurological, and autoimmune diseases. This review presents a comprehensive review of the most up-to-date literature on the epidemiology, and risk factors, as well as highlighting the gaps in our knowledge. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
25. Prevalence, Deaths, and Disability-Adjusted Life-Years Due to Asthma and Its Attributable Risk Factors in 204 Countries and Territories, 1990-2019.
- Author
-
Safiri, Saeid, Carson-Chahhoud, Kristin, Karamzad, Nahid, Sullman, Mark J.M., Nejadghaderi, Seyed Aria, Taghizadieh, Ali, Bell, Arielle Wilder, Kolahi, Ali-Asghar, Ansarin, Khalil, Mansournia, Mohammad Ali, Collins, Gary S., and Kaufman, Jay S.
- Subjects
WHEEZE ,GLOBAL burden of disease ,ASTHMA - Abstract
Background: Understanding global trends in the point prevalence, deaths, and disability-adjusted life-years (DALYs) for asthma will facilitate evidence-based decision-making.Research Question: What are the global, regional, and national burdens of asthma in 204 countries and territories between 1990 and 2019 by age, sex, and sociodemographic index (SDI)?Study Design and Methods: Publicly available data from the Global Burden of Disease study from 1990 through 2019 were used. All estimates were presented as counts and age-standardized rates per 100,000, along with their associated uncertainty intervals.Results: In 2019, the global age-standardized point prevalence and death rates for asthma were 3,415.5 and 5.8 per 100,000, which represent a 24% and 51.3% decrease since 1990, respectively. Moreover, in 2019, the global age-standardized DALY rate was 273.6 and the global point prevalence of asthma was highest in the group 5 to 9 years of age. Also in 2019, the United States (10,399.3) showed the highest age-standardized point prevalence rate of asthma. Generally, the burden of asthma decreased with increasing SDI. Globally, high BMI (16.9%), smoking (9.9%), and occupational asthmagens (8.8%) contributed to the 2019 asthma DALYs.Interpretation: Asthma remains an important public health issue, particularly in regions with low socioeconomic development. Future research is needed to examine thoroughly the associations asthma has with its risk factors and the factors impeding optimal self-management. Further research also is needed to understand and implement better the interventions that have reduced the burden of asthma. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
26. Burden of Transport-Related Injuries in the Eastern Mediterranean Region: A Systematic Analysis for the Global Burden of Disease Study 2017.
- Author
-
Safiri, Saeid, Sullman, Mark J. M., Lajunen, Timo, Hill, Tetiana, Almasi-Hashiani, Amir, Moradi-Lakeh, Maziar, Farzadfar, Farshad, Sepanlou, Sadaf G., Abu-Gharbieh, Eman, Aghamolaei, Teamur, Ahmad, Tauseef, Alghnam, Suliman A., Al-Hajj, Samar, Alipour, Vahid, Aljunid, Syed Mohamed, Anjomshoa, Mina, Ansari-Moghaddam, Alireza, Arabloo, Jalal, Bayati, Mohsen, and Bedi, Neeraj
- Subjects
- *
CAUSES of death , *TRAFFIC accidents , *AGE distribution , *LIFE expectancy , *SEX distribution , *DESCRIPTIVE statistics , *WOUNDS & injuries , *PEOPLE with disabilities - Abstract
Background: Transport-related injuries (TIs) are a substantial public health concern for all regions of the world. The present study quantified the burden of TIs and deaths in the Eastern Mediterranean region (EMR) in 2017 by sex and age. Methods: TIs and deaths were estimated by age, sex, country, and year using Cause of Death Ensemble modelling (CODEm) and DisMod-MR 2.1. Disability-adjusted life years (DALYs), which quantify the total burden of years lost due to premature death or disability, were also estimated per 100 000 population. All estimates were reported along with their corresponding 95% uncertainty intervals (UIs). Results: In 2017, there were 5.5 million (UI 4.9-6.2) transport-related incident cases in the EMR -- a substantial increase from 1990 (2.8 million; UI 2.5-3.1). The age-standardized incidence rate for the EMR in 2017 was 787 (UI 705.5-876.2) per 100 000, which has not changed significantly since 1990 (-0.9%; UI -4.7 to 3). These rates differed remarkably between countries, such that Oman (1303.9; UI 1167.3-1441.5) and Palestine (486.5; UI 434.5-545.9) had the highest and lowest age-standardized incidence rates per 100 000, respectively. In 2017, there were 185.3 thousand (UI 170.8-200.6) transport-related fatalities in the EMR -- a substantial increase since 1990 (140.4 thousand; UI 118.7-156.9). The age-standardized death rate for the EMR in 2017 was 29.5 (UI 27.1-31.9) per 100 000, which was 30.5% lower than that found in 1990 (42.5; UI 36.8-47.3). In 2017, Somalia (54; UI 30-77.4) and Lebanon (7.1; UI 4.8-8.6) had the highest and lowest age-standardized death rates per 100,000, respectively. The age-standardised DALY rate for the EMR in 2017 was 1,528.8 (UI 1412.5-1651.3) per 100 000, which was 34.4% lower than that found in 1990 (2,331.3; UI 1,993.1-2,589.9). In 2017, the highest DALY rate was found in Pakistan (3 454 121; UI 2 297 890-4 342 908) and the lowest was found in Bahrain (8616; UI 7670-9751). Conclusion: The present study shows that while road traffic has become relatively safer (measured by deaths and DALYs per 100 000 population), the number of transport-related fatalities in the EMR is growing and needs to be addressed urgently. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
27. Asthma and metabolic syndrome: a comprehensive systematic review and meta-analysis of observational studies.
- Author
-
Karamzad, Nahid, Izadi, Neda, Sanaie, Sarvin, Ahmadian, Elham, Eftekhari, Aziz, Sullman, Mark J. M., and Safiri, Saeid
- Subjects
METABOLIC syndrome risk factors ,ASTHMA ,CONFIDENCE intervals ,MEDICAL information storage & retrieval systems ,LONGITUDINAL method ,MEDLINE ,META-analysis ,SCIENTIFIC observation ,RISK assessment ,SYSTEMATIC reviews ,STATISTICAL significance ,METABOLIC syndrome ,DISEASE prevalence ,CROSS-sectional method ,STATISTICAL models ,ODDS ratio ,DISEASE complications - Abstract
Introduction: This study aimed to perform a meta-analysis on the prevalence of metabolic syndrome (MetS) among patients with asthma and to measure the association asthma has with MetS. Methods: The Web of Science, Medline, Scopus, Embase and Google Scholar were searched using the "Asthma", "Metabolic Syndrome", "Dysmetabolic Syndrome", "Cardiovascular Syndrome", "Insulin Resistance Syndrome", "Prevalence", "Odds Ratio", "Cross-Sectional Studies", and "Case-Control Studies" keywords. All observational studies reporting the prevalence of MetS among people with and without asthma were included in the study. In the presence of heterogeneity, random-effects models were used to pool the prevalence and odds ratios (OR), as measures of association in cross-sectional and case-control/ cohort studies, respectively. Results: The prevalence of MetS among patients with asthma (8 studies) and the OR comparing the prevalence of MetS among patients with and without asthma (5 studies) were pooled separately. The pooled prevalence of MetS among patients with asthma was found to be 25% (95% confidence interval (CI): 13%-38%). In contrast, the overall pooled OR for MetS in patients with asthma, compared to healthy controls, was 1.34 (95% CI: 0.91-1.76), which was not statistically significant. Conclusion: The prevalence of MetS was relatively high in patients with asthma. Furthermore, the odds of MetS was higher in patients with asthma, compared to healthy controls, although this difference was not statistically significant. More original studies among different populations are needed in order to more accurately examine the association between asthma and MetS, as well as the relationship asthma has with the individual components of MetS. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
28. Global, regional, and national burden of migraine in 204 countries and territories, 1990 to 2019.
- Author
-
Safiri, Saeid, Pourfathi, Hojjat, Eagan, Arielle, Mansournia, Mohammad Ali, Khodayari, Mohammad Taghi, Sullman, Mark J.M., Kaufman, Jay, Collins, Gary, Dai, Haijiang, Bragazzi, Nicola Luigi, and Kolahi, Ali-Asghar
- Subjects
- *
MIGRAINE aura , *MIGRAINE , *GLOBAL burden of disease , *MIDDLE-aged women , *MIDDLE-aged persons , *RESEARCH , *RESEARCH methodology , *DISEASE incidence , *WORLD health , *EVALUATION research , *COMPARATIVE studies , *DISEASE prevalence , *QUALITY-adjusted life years - Abstract
Abstract: Data from the Global Burden of Disease Study 2019 were used to report the burden of migraine in 204 countries and territories during the period 1990 to 2019, through a systematic analysis of point prevalence, annual incidence, and years lived with disability (YLD). In 2019, the global age-standardised point prevalence and annual incidence rate of migraine were 14,107.3 (95% Uncertainty Interval [UI] 12,270.3-16,239) and 1142.5 (95% UI 995.9-1289.4) per 100,000, an increase of 1.7% (95% UI 0.7%-2.8%) and 2.1% (95% UI 1.1%-2.8%) since 1990, respectively. Moreover, the global age-standardised YLD rate in 2019 was 525.5 (95% UI 78.8-1194), an increase of 1.5% (95% UI -4.4% to 3.3%) since 1990. The global point prevalence of migraine in 2019 was higher in females and increased by age up to the 40 to 44 age group, then decreased with increased age. Belgium (22,400.6 [95% UI: 19,305.2-26,215.8]), Italy (20,337.7 [95% UI: 17,724.7-23,405.8]), and Germany (19,436.4 [95% UI: 16,806.2-22,810.3]) had the 3 highest age-standardised point prevalence rates for migraine in 2019. In conclusion, there were large intercountry differences in the burden of migraine, and this burden increased significantly across the measurement period. These findings suggest that migraine care needs to be included within the health system to increase population awareness regarding the probable risk factors and treatment strategies especially among young adults and middle-aged women, as well as to increase the data on migraines. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
29. Prevalence, Deaths, and Disability-Adjusted Life-Years Due to Asthma and Its Attributable Risk Factors in 204 Countries and Territories, 1990-2019
- Author
-
Kristin Carson-Chahhoud, Gary S. Collins, Ali Taghizadieh, Jay S. Kaufman, Arielle Wilder Bell, Mark J.M. Sullman, Ali-Asghar Kolahi, Seyed Aria Nejadghaderi, Mohammad Ali Mansournia, Khalil Ansarin, Saeid Safiri, Nahid Karamzad, Safiri, Saeid, Carson-Chahhoud, Kristin, Karamzad, Nahid, Sullman, Mark JM, Nejadghaderi, Seyed Aria, Taghizadieh, Ali, Bell, Arielle Wilder, Kolahi, Ali-Asghar, Ansarin, Khalil, Mansournia, Mohammad Ali, Collins, Gary S, and Kaufman, Jay S
- Subjects
Male ,Pulmonary and Respiratory Medicine ,medicine.medical_specialty ,prevalence ,Prevalence ,Global Health ,Critical Care and Intensive Care Medicine ,burden ,Risk Factors ,Environmental health ,Epidemiology ,medicine ,Humans ,risk factors ,Disability-adjusted life year ,Asthma ,business.industry ,Public health ,Mortality rate ,Disability-Adjusted Life Years ,asthma ,global ,medicine.disease ,mortality ,Years of potential life lost ,Attributable risk ,Female ,epidemiology ,Cardiology and Cardiovascular Medicine ,business - Abstract
Background Understanding global trends in the point prevalence, deaths and disability adjusted life years (DALYs) for asthma will facilitate evidence-based decision making. Research Question What is the global, regional and national burden of asthma in 204 countries and territories between 1990 and 2019, by age, sex and socio-demographic index (SDI)? Study Design and Methods Publicly available data from the Global Burden of Disease study were used over the period 1990 to 2019. All estimates were presented as counts and age-standardised rates per 100,000, along with their associated uncertainty intervals (UIs). Results In 2019, the global age-standardised point prevalence and death rates for asthma were 3415.5 and 5.8 per 100,000, which represent a 24% and 51.3% decrease since 1990, respectively. Moreover, in 2019 the global age-standardised DALY rate was 273.6 and the global point prevalence of asthma was highest in the 5-9 age group. Also in 2019, the USA (10399.3) had the highest age-standardised point prevalence rate of asthma. Generally, the burden of asthma decreased with increasing socio-demographic index (SDI). Globally, high body mass index (16.9%), smoking (9.9%) and occupational asthmagens (8.8%) contributed to the 2019 asthma DALYs. Interpretation Asthma remains an important public health issue, particularly in regions with low socio-economic development. Future research is needed to thoroughly examine the associations asthma has with its risk factors and the factors impeding optimal self-management. Further research is also needed to understand and better implement the interventions that have reduced the burden of asthma.
- Published
- 2022
30. Global, Regional and National Burden of Cancers Attributable to High Fasting Plasma Glucose in 204 Countries and Territories, 1990-2019
- Author
-
Saeid Safiri, Seyed Aria Nejadghaderi, Nahid Karamzad, Jay S. Kaufman, Kristin Carson-Chahhoud, Nicola Luigi Bragazzi, Mark J. M. Sullman, Mohammad Reza Beyranvand, Mohammad Ali Mansournia, Amir Almasi-Hashiani, Gary S. Collins, Ali-Asghar Kolahi, Safiri, Saeid, Nejadghaderi, Seyed Aria, Karamzad, Nahid, Kaufman, Jay S, Carson-Chahhoud, Kristin, Bragazzi, Nicola Luigi, Sullman, Mark JM, Beyranvand, Mohammad Reza, Mansournia, Mohammad Ali, Almasi-Hashiani, Amir, Collins, Gary S, and Kolahi, Ali Asghar
- Subjects
Blood Glucose ,Male ,Endocrinology, Diabetes and Metabolism ,neoplasms ,Fasting ,mortality ,Global Burden of Disease ,Neoplasms ,diabetes mellitus ,incidence ,Diabetes Mellitus ,Humans ,epidemiology ,Female ,Quality-Adjusted Life Years ,Aged - Abstract
BackgroundTo report the burden of cancers attributable to high fasting plasma glucose (HFPG) by sex, age, location, cancer type and Socio-demographic Index (SDI) over the period 1990 to 2019 for 204 countries and territories.MethodsUsing the Comparative Risk Assessment approach of Global Burden of Disease (GBD) study 2019, the burden of cancers attributable to HFPG was reported in 1990 and 2019.ResultsGlobally, in 2019 there were an estimated 419.3 thousand cancer deaths (95% UI: 115.7 to 848.5) and 8.6 million cancer DALYs (2.4 to 17.6) attributable to HFPG. By sex, 4.6 (1.1 to 9.9) and 4.0 (1.1 to 8.4) million global cancer DALYs were attributable to HFPG in men and women, respectively. The global age-standardized death and DALY rates of cancers attributable to HFPG (per 100,000) have increased by 27.8% (20.5 to 38.7%) and 24.5% (16.4 to 35.6%), respectively, since 1990. High-income North America (9.5 [2.7 to 18.8]) and Eastern Sub-Saharan Africa (2.0 [0.5 to 4.2]) had the highest and lowest regional age-standardized death rates, respectively, for cancers attributable to HFPG. In 2019, the global number of attributable cancer DALYs were highest in 65-69 age group. Moreover, there was an overall positive association between SDI and the regional age-standardized DALY rate for HFPG-attributable cancers.ConclusionsHFPG was associated with more burden in 2019. Preventive programs for diabetes and screening of individuals with diabetes for cancers, especially in older males living in developed countries, are required to arrest the large increases in HFPG-attributable cancers.
- Published
- 2022
- Full Text
- View/download PDF
31. The burden of stroke and its attributable risk factors in the Middle East and North Africa region, 1990–2019
- Author
-
Mehran Jaberinezhad, Mehdi Farhoudi, Seyed Aria Nejadghaderi, Mahasti Alizadeh, Mark J. M. Sullman, Kristin Carson-Chahhoud, Gary S. Collins, Saeid Safiri, Jaberinezhad, Mehran, Farhoudi, Mehdi, Nejadghaderi, Seyed Aria, Alizadeh, Mahasti, Sullman, Mark JM, Carson-Chahhoud, Kristin, Collins, Gary S, and Safiri, Saeid
- Subjects
Adult ,Aged, 80 and over ,Male ,Multidisciplinary ,Adolescent ,Infant ,Middle Aged ,North Africa ,stroke ,Stroke ,Young Adult ,Middle East ,Africa, Northern ,Cost of Illness ,Socioeconomic Factors ,Risk Factors ,Child, Preschool ,Prevalence ,Humans ,Female ,epidemiology ,Quality-Adjusted Life Years ,Child ,Aged - Abstract
Stroke is one of the leading causes of mortality and morbidity across the globe. Providing comprehensive data on the burden of stroke in the Middle East and North Africa (MENA) could be useful for health policy makers in the region. Therefore, this article reported the burden of stroke and its attributable risk factors between 1990 and 2019 by age, sex, type of stroke, and socio-demographic index. Data on the point prevalence, death, and disability-adjusted life-years (DALYs), due to stroke, were retrieved from the Global Burden of Disease study 2019 for the 21 countries located in the MENA region from 1990 to 2019. The counts and age-standardised rates (per 100,000) were presented, along with their corresponding 95% uncertainty intervals (UIs). In 2019, the regional age-standardised point prevalence and death rates of stroke were 1537.5 (95% UI: 1421.9–1659.9) and 87.7 (78.2–97.6) per 100,000, which represent a 0.5% (− 2.3 to 1.1) and 27.8% (− 35.4 to − 16) decrease since 1990, respectively. Moreover, the regional age-standardised DALY rate in 2019 was 1826.2 (1635.3–2026.2) per 100,000, a 32.0% (− 39.1 to − 23.3) decrease since 1990. In 2019, Afghanistan [3498.2 (2508.8–4500.4)] and Lebanon [752.9 (593.3–935.9)] had the highest and lowest age-standardised DALY rates, respectively. Regionally, the total number of stroke cases were highest in the 60–64 age group and was more prevalent in women in all age groups. In addition, there was a general negative association between SDI and the burden of stoke from 1990 to 2019. Also, in 2019, high systolic blood pressure [53.5%], high body mass index [39.4%] and ambient particulate air pollution [27.1%] made the three largest contributions to the burden of stroke in the MENA region. The stroke burden has decreased in the MENA region over the last three decades, although there are large inter-country differences. Preventive programs should be implemented which focus on metabolic risk factors, especially among older females in low SDI countries.
- Published
- 2022
32. Prevalence, incidence and years lived with disability due to polycystic ovary syndrome in 204 countries and territories, 1990-2019
- Author
-
Saeid Safiri, Maryam Noori, Seyed Aria Nejadghaderi, Nahid Karamzad, Kristin Carson-Chahhoud, Mark J M Sullman, Gary S Collins, Ali-Asghar Kolahi, Jodie Avery, Safiri, Saeid, Noori, Maryam, Nejadghaderi, Seyed Aria, Karamzad, Nahid, Carson-Chahhoud, Kristin, Sullman, Mark JM, Collins, Gary S, Kolahi, Ali Asghar, and Avery, Jodie
- Subjects
global burden of disease ,Incidence ,prevalence ,Rehabilitation ,Obstetrics and Gynecology ,Disability-Adjusted Life Years ,Iran ,Global Health ,years lived with disability ,Global Burden of Disease ,Reproductive Medicine ,socio-demographic index ,incidence ,PCOS ,Prevalence ,Humans ,epidemiology ,Female ,Polycystic Ovary Syndrome - Abstract
STUDY QUESTION What is the global, regional and national burden of polycystic ovary syndrome (PCOS), by age and socio-demographic index (SDI), over the period 1990–2019? SUMMARY ANSWER In 2019, the global age-standardized point prevalence, incidence and years lived with disability (YLD) of PCOS were 30.4, 29.5 and 29.9 per 100 000 population, respectively. WHAT IS KNOWN ALREADY Data from the Global Burden of Disease (GBD) study 2017 showed that the global age-standardized PCOS incidence rate increased 1.45% over the period 1990–2017. STUDY DESIGN, SIZE, DURATION A systematic analysis of the PCOS prevalence, incidence and YLDs across 204 countries and territories was performed. PARTICIPANTS/MATERIALS, SETTING, METHODS Data on the point prevalence, annual incidence and YLDs due to PCOS were retrieved from the GBD study 2019 for 204 countries and territories from 1990 to 2019. The counts and age-standardized rates (per 100 000) are presented, along with their corresponding 95% uncertainty intervals (UIs). MAIN RESULTS AND THE ROLE OF CHANCE In 2019, the global age-standardized point prevalence and annual incidence rates for PCOS were 1677.8 (95% UI: 1166.0 to 2192.4) and 59.8 (95% UI: 41.7 to 78.9) per 100 000, which represents a 30.4% and 29.5% increase since 1990, respectively. Moreover, the global age-standardized YLD rate in 2019 was 14.7 (6.3–29.5), an increase of 29.9% since 1990. In 2019, Italy (7897.0), Japan (6298.7) and New Zealand (5419.1) had the highest estimated age-standardized point prevalences of PCOS. Globally, the number of prevalent cases and the point prevalence of PCOS peaked in the 25–29 years and 40–44 years age groups, respectively. Positive associations were found between the burden of PCOS and the SDI at the regional and national levels. LIMITATIONS, REASONS FOR CAUTION Variations in how PCOS was defined is a major limitation that prevents valid comparisons between different regions. WIDER IMPLICATIONS OF THE FINDINGS Globally, the burden of PCOS has increased at an alarming rate, making it a major public health concern. Increasing public awareness about this common condition, improving management options and increasing support to reduce factors which lead to further complications, need to be public health priorities. STUDY FUNDING/COMPETING INTEREST(S) The Bill and Melinda Gates Foundation, who were not involved in any way in the preparation of this manuscript, funded the GBD study. The Shahid Beheshti University of Medical Sciences, Tehran, Iran (Grant No. 28709) also supported the present report. The authors declare no competing interests. TRIAL REGISTRATION NUMBER N/A.
- Published
- 2021
33. Burden of ischemic heart disease and its attributable risk factors in 204 countries and territories, 1990-2019
- Author
-
Saeid Safiri, Nahid Karamzad, Kuljit Singh, Kristin Carson-Chahhoud, Cobi Adams, Seyed Aria Nejadghaderi, Amir Almasi-Hashiani, Mark J M Sullman, Mohammad Ali Mansournia, Nicola Luigi Bragazzi, Jay S Kaufman, Gary S Collins, Ali-Asghar Kolahi, Safiri, Saeid, Karamzad, Nahid, Singh, Kuljit, Carson-Chahhoud, Kristin, Adams, Cobi, Nejadghaderi, Seyed Aria, Almasi-Hashiani, Amir, Sullman, Mark JM, Mansournia, Mohammad Ali, Bragazzi, Nicola Luigi, Kaufman, Jay S, Collins, Gary S, and Kolahi, Ali Asghar
- Subjects
Male ,global burden of disease ,Epidemiology ,Myocardial Ischemia ,Global Health ,ischemic heart disease ,Global Burden of Disease ,risk factor ,Risk Factors ,Prevalence ,Humans ,epidemiology ,Female ,cardiovascular diseases ,Quality-Adjusted Life Years ,Cardiology and Cardiovascular Medicine - Abstract
Aims To report the prevalence, deaths, and disability-adjusted life years (DALYs) associated with ischemic heart disease (IHD) and its attributable risk factors in 204 countries and territories from 1990 to 2019, by age, sex, and socio-demographic index (SDI). Methods and results Ischemic heart disease was defined as acute myocardial infarction (MI) and chronic IHD (angina; asymptomatic IHD following MI). Cause of death ensemble modelling was used to produce fatality estimates. The prevalence of the non-fatal sequalae of IHD was estimated using DisMod MR 2.1. All estimates were presented as counts and age-standardized rates per 100 000 population. In 2019, IHD accounted for 197.2 million (177.7–219.5) prevalent cases, 9.1 million (8.4–9.7) deaths, and 182.0 million (170.2–193.5) DALYs worldwide. There were decreases in the global age-standardized prevalence rates of IHD [−4.6% (−5.7, −3.6)], deaths [−30.8% (−34.8, −27.2)], and DALYs [−28.6% (−33.3, −24.2)] from 1990 to 2019. In 2019, the global prevalence and death rates of IHD were higher among males across all age groups, while the death rate peaked in the oldest group for both sexes. A negative association was found between the age-standardized DALY rates and SDI. Globally, high systolic blood pressure (54.6%), high low-density lipoprotein cholesterol (46.6%), and smoking (23.9%) were the three largest contributors to the DALYs attributable to IHD. Conclusion Although the global age-standardized prevalence, death, and DALY rates all decreased. Prevention and control programmes should be implemented to reduce population exposure to risk factors, reduce the risk of IHD in high-risk populations, and provide appropriate care for communities.
- Published
- 2021
34. Epidemiology, prognosis and management of potassium disorders in Covid‐19
- Author
-
Kristin Carson-Chahhoud, Saeid Safiri, Mark J.M. Sullman, Seyed Aria Nejadghaderi, Ali-Asghar Kolahi, Maryam Noori, Noori, Maryam, Nejadghaderi, Seyed A., Sullman, Mark J.M., Carson-Chahhoud, Kristin, Kolahi, Ali Asghar, and Safiri, Saeid
- Subjects
0301 basic medicine ,medicine.medical_specialty ,Hyperkalemia ,030106 microbiology ,review ,Review ,Disease ,urologic and male genital diseases ,medicine.disease_cause ,SARS‐CoV‐2 ,03 medical and health sciences ,chemistry.chemical_compound ,Virology ,Lactate dehydrogenase ,White blood cell ,Internal medicine ,Epidemiology ,hypokalemia ,medicine ,Humans ,Coronavirus ,Covid‐19 ,Creatinine ,SARS-CoV-2 ,business.industry ,COVID-19 ,nutritional and metabolic diseases ,serum potassium ,Prognosis ,Hypokalemia ,030104 developmental biology ,Infectious Diseases ,medicine.anatomical_structure ,chemistry ,Potassium ,medicine.symptom ,business ,Biomarkers - Abstract
Coronavirus disease (Covid-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is currently the largest health crisis facing most countries. Several factors have been linked with a poor prognosis for this disease, including demographic factors, pre-existing comorbidities and laboratory parameters such as white blood cell count, D-dimer, C-reactive protein, albumin, lactate dehydrogenase, creatinine and electrolytes. Electrolyte abnormalities particularly potassium disorders are common among Covid-19 patients. Based on our pooled analysis, hypokalemia and hyperkalemia occur in 24.3% and 4.15% of Covid-19 patients, respectively. Potassium level deviation from the normal range may increase the chances of unfavorable outcomes and even death. Therefore, this article reviewed the epidemiology of potassium disorders and explained how hypokalemia and hyperkalemia are capable of deteriorating cardiac outcomes and the prognosis of Covid-19 for infected patients. The article finishes by highlighting some important considerations in the management of hypokalemia and hyperkalemia in these patients. Refereed/Peer-reviewed
- Published
- 2021
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.